Product image of Maysiglu (Sitagliptin) supplied by GNH India

Maysiglu

Active Ingredient:
Sitagliptin
Origin:
EU

Maysiglu (Sitagliptin)

Sitagliptin, the active ingredient in Maysiglu, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as an oral tablet for oral use. It belongs to the oral hypoglycemic therapeutic class and is prescribed to improve glycemic control in adults with type 2 diabetes mellitus, especially when blood glucose remains inadequately controlled by diet and exercise alone.

GNH India supplies Maysiglu as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU quality standards and providing reliable global distribution.

Manufacturer / TM Owner

Krka, D.D., Novo Mesto

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Maysiglu (sitagliptin) is used in the management of type 2 diabetes, a chronic metabolic disorder characterized by insulin resistance.

  • Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels.
  • Combination with metformin: provides additional glycemic reduction when used together.
  • Adjunct to diet and exercise: serves as an oral therapy for patients whose glucose remains uncontrolled by lifestyle measures alone.

How It Works

  • Sitagliptin selectively inhibits the dipeptidyl peptidase‑4 (DPP‑4) enzyme, preventing the breakdown of incretin hormones such as GLP‑1 and GIP. Elevated incretin levels enhance glucose‑dependent insulin secretion from pancreatic β‑cells and suppress glucagon release from α‑cells, resulting in improved post‑prandial and overall glycemic control without causing hypoglycaemia when used alone.

Side Effects

Common Side Effects

  • Nasopharyngitis: mild upper‑respiratory tract infection symptoms.
  • Headache: transient mild to moderate head discomfort.
  • Gastrointestinal upset: includes nausea, abdominal pain or dyspepsia.
  • Dizziness: occasional light‑headed sensation.
  • Upper respiratory infection: mild cough or sore throat.

Serious or Rare Side Effects

  • Pancreatitis: severe abdominal pain requiring immediate medical attention.
  • Severe allergic reactions: including rash, angioedema or anaphylaxis.
  • Hepatic injury: elevated liver enzymes or hepatitis.
  • Joint pain: unexplained arthralgia that may be disabling.
  • Bullous skin disorders: rare blistering skin conditions.

Precautions & Warnings

Before initiating therapy, consider the following precautions:

  • Renal function: assess creatinine clearance and adjust dose if needed.
  • Hypersensitivity: discontinue immediately if signs of allergic reaction appear.
  • Concomitant insulin or sulfonylureas: monitor for hypoglycaemia.
  • Elderly patients: start with lower dose and observe tolerance.
  • Pregnancy and lactation: use only if potential benefit justifies the risk.
  • Store at ambient temperature: keep in the original container, protect from moisture and light.

Avoid Interactions

Sitagliptin may interact with several medicines; monitoring is advised.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase sitagliptin exposure.
  • Insulin secretagogues (e.g., sulfonylureas): heightened risk of hypoglycaemia.
  • Rifampin: may reduce sitagliptin effectiveness.

Moderate Interactions (Monitor Closely)

  • Diuretics: monitor renal function and electrolytes.
  • ACE inhibitors: watch for blood pressure changes.
  • Warfarin: periodic INR checks are recommended.

Frequently Asked Questions

Maysiglu contains sitagliptin, a DPP‑4 inhibitor indicated to improve blood‑sugar control in adults with type 2 diabetes mellitus, either as monotherapy or in combination with other antidiabetic agents such as metformin.

Sitagliptin blocks the DPP‑4 enzyme, which normally degrades the incretin hormones GLP‑1 and GIP. By preserving these hormones, the drug enhances glucose‑dependent insulin release and reduces glucagon secretion, leading to lower blood glucose levels.

The appropriate dose of Maysiglu is determined by a qualified prescriber based on the individual’s renal function, glycaemic targets and any concomitant medications. Patients should follow the dosing instructions provided by their healthcare professional.

Safety data for sitagliptin in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and only under medical supervision.

To place an order, submit an enquiry on the Maysiglu product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with sulfonylureas, sitagliptin has a lower risk of causing hypoglycaemia because its insulin‑stimulating effect is glucose‑dependent. Relative to other DPP‑4 inhibitors, efficacy and safety profiles are similar; choice often depends on formulation, cost and individual patient factors.

Maysiglu should be stored at ambient temperature, below 25 °C, in the original blister pack or container. Protect the product from excess moisture, heat and direct sunlight to maintain potency throughout its shelf life.

Maysiglu is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with water and not chewed or crushed unless otherwise directed by a healthcare professional.

The most serious adverse events to monitor are acute pancreatitis, severe allergic reactions such as anaphylaxis, and rare skin disorders like bullous pemphigoid. Patients experiencing persistent abdominal pain, rash, or swelling should seek immediate medical attention.

Maysiglu is contraindicated in individuals with a known hypersensitivity to sitagliptin or any excipients in the formulation. Caution is also advised for patients with severe renal impairment, as dose adjustment may be required, and for those with a history of pancreatitis.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Sitagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT